Genetic Variants in SGLT1, Glucose Tolerance, and Cardiometabolic Risk

Journal of the American College of Cardiology

Volumn 72, Issue 15, 2018, Pages 1763-1773

  Seidelmann, Sara B ^a   Feofanova, Elena ^b   Yu, Bing ^b   Franceschini, Nora ^c   Claggett, Brian ^a   Kuokkanen, Mikko ^d,e   Puolijoki, Hannu ^f   Ebeling, Tapani ^g   Perola, Markus ^d,e   Salomaa, Veikko ^d   Shah, Amil ^a   Coresh, Josef ^h   Selvin, Elizabeth ^h   MacRae, Calum A ^a   Cheng, Susan ^a   Boerwinkle, Eric ^b,i   Solomon, Scott D ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^c IL   (United States)

^d NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^e UNIVERSITY OF HELSINKI   (Finland)

^f South Ostrobothnia Hospital District   (Finland)

^g OULU UNIVERSITY HOSPITAL   (Finland)

^h JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

glucose tolerance; Mendelian randomization; SGLT1

Indexed keywords

ALANINE; ASPARAGINE; GLUCOSE; GLUTAMINE; HISTIDINE; SERINE; SODIUM GLUCOSE COTRANSPORTER 1; THREONINE; SLC5A1 PROTEIN, HUMAN;

ADULT; AFRICAN; AMERICAN; ARTICLE; ATHEROSCLEROSIS; CARDIOMETABOLIC RISK; CARDIOVASCULAR RISK; CLINICAL OUTCOME; CLINICAL STUDY; COHORT ANALYSIS; COMMUNITY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETES MELLITUS; EUROPEAN; FEMALE; FINN (CITIZEN); GENETIC VARIABILITY; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HAPLOTYPE; HAZARD RATIO; HEART FAILURE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MENDELIAN RANDOMIZATION ANALYSIS; MISSENSE MUTATION; MORTALITY; OBESITY; ODDS RATIO; ORAL GLUCOSE TOLERANCE TEST; POPULATION GENETICS; PREVALENCE; PRIORITY JOURNAL; SGLT1 GENE; WHOLE EXOME SEQUENCING; CARDIOVASCULAR DISEASE; CAUCASIAN; GENETIC VARIATION; GENETICS; GLUCOSE TOLERANCE TEST; HYPERGLYCEMIA; INTESTINE ABSORPTION; LOSS OF FUNCTION MUTATION; METABOLISM; MIDDLE AGED; OUTCOME ASSESSMENT; PROCEDURES; PROTECTION; RISK ASSESSMENT; UNITED STATES;

CARDIOVASCULAR DISEASES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC VARIATION; GLUCOSE; GLUCOSE TOLERANCE TEST; HUMANS; HYPERGLYCEMIA; INTESTINAL ABSORPTION; LOSS OF FUNCTION MUTATION; MALE; MENDELIAN RANDOMIZATION ANALYSIS; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PROTECTIVE FACTORS; RISK ASSESSMENT; SODIUM-GLUCOSE TRANSPORTER 1; UNITED STATES; WHOLE EXOME SEQUENCING;

EID: 85053768203     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2018.07.061     Document Type: Article

References (36)

1. Martin, M.G., Turk, E., Lostao, M.P., Kerner, C., Wright, E.M., Defects in Na+/glucose cotransporter (SGLT1) trafficking and function cause glucose-galactose malabsorption. Nat Genet 12 (1996), 216–220.
2. Turk, E., Zabel, B., Mundlos, S., Dyer, J., Wright, E.M., Glucose/galactose malabsorption caused by a defect in the Na+/glucose cotransporter. Nature 350 (1991), 354–356.
3. Lam, J.T., Martin, M.G., Turk, E., et al. Missense mutations in SGLT1 cause glucose-galactose malabsorption by trafficking defects. Biochim Biophys Acta 1453 (1999), 297–303.
4. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. Am J Epidemiol 129 (1989), 687–702.
5. Hu, F.B., Rimm, E., Smith-Warner, S.A., et al. Reproducibility and validity of dietary patterns assessed with a food-frequency questionnaire. Am J Clin Nutr 69 (1999), 243–249.
6. White, A.D., Folsom, A.R., Chambless, L.E., et al. Community surveillance of coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) Study: methods and initial two years’ experience. J Clin Epidemiol 49 (1996), 223–233.
7. Selvin, E., Steffes, M.W., Zhu, H., et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 362 (2010), 800–811.
8. Rosamond, W.D., Chang, P.P., Baggett, C., et al. Classification of heart failure in the atherosclerosis risk in communities (ARIC) study: a comparison of diagnostic criteria. Circ Heart Fail 5 (2012), 152–159.
9. Bainbridge, M.N., Wang, M., Wu, Y., et al. Targeted enrichment beyond the consensus coding DNA sequence exome reveals exons with higher variant densities. Genome Biol, 12, 2011, R68.
10. Challis, D., Yu, J., Evani, U.S., et al. An integrative variant analysis suite for whole exome next-generation sequencing data. BMC Bioinformatics, 13, 2012, 8.
11. Li, H., Durbin, R., Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25 (2009), 1754–1760.
12. DePristo, M.A., Banks, E., Poplin, R., et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet 43 (2011), 491–498.
13. Danecek, P., Auton, A., Abecasis, G., et al. The variant call format and VCFtools. Bioinformatics 27 (2011), 2156–2158.
14. Borodulin, K., Tolonen, H., Jousilahti, P., et al. Cohort profile: the national FINRISK Study. Int J Epidemiol, 47, 2018, 696i.
15. Borodulin, K., Vartiainen, E., Peltonen, M., et al. Forty-year trends in cardiovascular risk factors in Finland. Eur J Public Health 25 (2015), 539–546.
16. Konttinen, H., Mannisto, S., Sarlio-Lahteenkorva, S., Silventoinen, K., Haukkala, A., Emotional eating, depressive symptoms and self-reported food consumption. A population-based study. Appetite 54 (2010), 473–479.
17. Price, A.L., Patterson, N.J., Plenge, R.M., Weinblatt, M.E., Shadick, N.A., Reich, D., Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 38 (2006), 904–909.
18. Kircher, M., Witten, D.M., Jain, P., O'Roak, B.J., Cooper, G.M., Shendure, J., A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet 46 (2014), 310–315.
19. Pontremoli, C., Mozzi, A., Forni, D., et al. Natural selection at the brush-border: adaptations to carbohydrate diets in humans and other mammals. Genome Biol Evol 7 (2015), 2569–2584.
20. Gorboulev, V., Schurmann, A., Vallon, V., et al. Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes 61 (2012), 187–196.
21. Powell, D.R., DaCosta, C.M., Gay, J., et al. Improved glycemic control in mice lacking Sglt1 and Sglt2. Am J Physiol Endocrinol Metab 304 (2013), E117–E130.
22. Osswald, C., Baumgarten, K., Stumpel, F., et al. Mice without the regulator gene Rsc1A1 exhibit increased Na+-D-glucose cotransport in small intestine and develop obesity. Mol Cell Biol 25 (2005), 78–87.
23. Li, M., Maruthur, N.M., Loomis, S.J., et al. Genome-wide association study of 1,5-anhydroglucitol identifies novel genetic loci linked to glucose metabolism. Sci Rep, 7, 2017, 2812.
24. Dobbins, R.L., Greenway, F.L., Chen, L., et al. Selective sodium-dependent glucose transporter 1 inhibitors block glucose absorption and impair glucose-dependent insulinotropic peptide release. Am J Physiol Gastrointest Liver Physiol 308 (2015), G946–G954.
25. Powell, D.R., Smith, M., Greer, J., et al. LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose. J Pharmacol Exp Ther 345 (2013), 250–259.
26. Shibazaki, T., Tomae, M., Ishikawa-Takemura, Y., et al. KGA-2727, a novel selective inhibitor of a high-affinity sodium glucose cotransporter (SGLT1), exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther 342 (2012), 288–296.
27. Tolhurst, G., Heffron, H., Lam, Y.S., et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes 61 (2012), 364–371.
28. Flint, A., Raben, A., Astrup, A., Holst, J.J., Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 101 (1998), 515–520.
29. Takahashi, A., Ihara, M., Yamazaki, S., Asanuma, H., Asakura, M., Kitakaze, M., Impact of either GLP-1 agonists or DPP-4 inhibitors on pathophysiology of heart failure. Int Heart J 56 (2015), 372–376.
30. Ramratnam, M., Sharma, R.K., D'Auria, S., et al. Transgenic knockdown of cardiac sodium/glucose cotransporter 1 (SGLT1) attenuates PRKAG2 cardiomyopathy, whereas transgenic overexpression of cardiac SGLT1 causes pathologic hypertrophy and dysfunction in mice. J Am Heart Assoc, 3, 2014.
31. Meng, L., Uzui, H., Guo, H., Tada, H., Role of SGLT1 in high glucose level-induced MMP-2 expression in human cardiac fibroblasts. Mol Med Rep 17 (2018), 6887–6892.
32. Lehmann, A., Hornby, P.J., Intestinal SGLT1 in metabolic health and disease. Am J Physiol Gastrointest Liver Physiol 310 (2016), G887–G898.
33. Zinman, B., Wanner, C., Lachin, J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
34. Neal, B., Perkovic, V., Mahaffey, K.W., et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377 (2017), 644–657.
35. Zambrowicz, B., Ogbaa, I., Frazier, K., et al. Effects of LX4211, a dual sodium-dependent glucose cotransporters 1 and 2 inhibitor, on postprandial glucose, insulin, glucagon-like peptide 1, and peptide tyrosine tyrosine in a dose-timing study in healthy subjects. Clin Ther 35 (2013), 1162–1173.e8.
36. Garg, S.K., Henry, R.R., Banks, P., et al. Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med 377 (2017), 2337–2348.